Publications by authors named "Li-Qin Ping"
The immune regulator galectin-9 (Gal-9) is commonly involved in the regulation of cell proliferation, but with various impacts depending on the cell type. Here, we revealed that Gal-9 expression was persistently increased in Epstein-Barr virus (EBV)-infected primary B cells from the stage of early infection to the stage of mature lymphoblastoid cell lines (LCLs). This sustained upregulation paralleled that of gene sets related to cell proliferation, such as oxidative phosphorylation, cell cycle activation, and DNA replication.
View Article and Find Full Text PDFPurpose: Some studies have indicated that using 500 mg/m rituximab combined with CHOP-14 may be beneficial for elderly men but not women with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefit of escalated doses of rituximab with CHOP-21 as the first-line treatment in male patients with DLBCL.
Methods: We performed a retrospective cohort study to analyze the survival benefit of rituximab 500 mg/m plus the CHOP-21 regimen (Escalated-R-CHOP-21) as the first-line treatment compared with using rituximab 375 mg/m plus the CHOP-21 regimen (Standard-R-CHOP-21) in men with DLBCL.
Although PD-1/PD-L1 blockade therapy confers salutary effects across cancer types, their efficacy in Extranodal Natural killer/T-cell lymphoma (ENKTCL) patients is limited and unpredictable. Here, we comprehensively evaluated the expression profile of a panel of immune-regulatory makers to identify novel prognostic biomarkers and/or therapeutic targets for this malignancy. Using immunohistochemistry and multiplex immunofluorescence, we found that the expression of VISTA (88.
View Article and Find Full Text PDFArticle Synopsis
- Peri-engraftment respiratory distress syndrome (PERDS) is a serious complication that can occur after autologous stem cell transplantation (ASCT), marked by fever, breathing difficulties, and low oxygen levels during neutrophil recovery.
- A study of 260 lymphoma patients revealed that 6.1% developed PERDS, with prior anti-PD-1 therapy and lung disease history identified as significant risk factors.
- Those who received anti-PD-1 treatment had a notably higher risk of both PERDS and transplant-related mortality, with sintilimab showing a trend towards increased PERDS incidence compared to other therapies.
At present, autologous stem cell transplantation (ASCT) is considered as an optional consolidation therapy for natural killer/T-cell lymphoma (NKTCL). However, the high-risk patients undergoing ASCT are not clear enough. In this study, 56 patients with advanced staged or relapsed/refractory (R/R) NKTCL undergoing ASCT were reviewed.
View Article and Find Full Text PDF